A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity

BACKGROUND: Colorectal cancer (CRC) is one of the most common malignancies and the patient survival rate remains unacceptably low. The anti-programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody-based immune checkpoint inhibitors have been added to CRC treatment regimens, how...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Lian-sheng, Cheng, Yong-feng, Liu, Wen-ting, Shen, Aolin, Zhang, Dayan, Xu, Tingjuan, Yin, Wu, Cheng, Min, Ma, Xiaopeng, Wang, Fengrong, Zhao, Qun, Zeng, Xiaoli, Zhang, Yan, Shen, Guodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461191/
https://www.ncbi.nlm.nih.gov/pubmed/36076251
http://dx.doi.org/10.1186/s12967-022-03619-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461191/
https://www.ncbi.nlm.nih.gov/pubmed/36076251
http://dx.doi.org/10.1186/s12967-022-03619-w

Ejemplares similares